Kaiser H J, Flammer J, Stümpfig D, Hendrickson P
University Eye Clinic, Basel, Switzerland.
Surv Ophthalmol. 1994 May;38 Suppl:S156-9; discussion S160. doi: 10.1016/0039-6257(94)90060-4.
In a prospective, randomized, double-masked study, 44 patients with primary open-angle glaucoma were treated either with 0.5% betaxolol or 0.5% timolol in both eyes twice daily. Twenty-nine patients could be followed up for 48 months. Seventeen of these patients were treated with betaxolol and 12 with timolol. Each examination included visual field measurements with an Octopus automated perimeter 201 (Program G1), intraocular pressure measurement, funduscopy, as well as pulse and arterial blood pressure measurements. Both drugs lowered in the intraocular pressure. This reduction was slightly but not statistically significantly higher in the timolol-treated group. However, the visual fields improved more in the betaxolol group. Patients treated with betaxolol had significantly smaller averaged mean defects (p < 0.05) and higher averaged mean sensitivities (p < 0.05, Wilcoxon rank score text) than did timolol-treated patients at months 3, 6, 12, and 18. Thereafter, the difference between the two groups was not statistically significant in this relatively small sample size. For betaxolol patients the cumulative area-under-the-curve analysis for the worse eye yielded significantly larger mean sensitivities beyond month 12 (exception: month 30; p < 0.05) and significantly smaller mean defects beyond month 6 (p < 0.05).
在一项前瞻性、随机、双盲研究中，44例原发性开角型青光眼患者双眼每日两次使用0.5%倍他洛尔或0.5%噻吗洛尔进行治疗。29例患者可随访48个月。其中17例患者接受倍他洛尔治疗，12例接受噻吗洛尔治疗。每次检查包括使用Octopus自动视野计201（程序G1）进行视野测量、眼压测量、眼底镜检查以及脉搏和动脉血压测量。两种药物均降低了眼压。噻吗洛尔治疗组的眼压降低幅度略大，但无统计学显著差异。然而，倍他洛尔组的视野改善更明显。在第3、6、12和18个月时，接受倍他洛尔治疗的患者平均缺损明显较小（p<0.05），平均敏感度明显较高（p<0.05，Wilcoxon秩和检验），优于接受噻吗洛尔治疗的患者。此后，在这个相对较小的样本量中，两组之间的差异无统计学意义。对于使用倍他洛尔的患者，较差眼的曲线下面积累积分析显示，12个月后平均敏感度明显更高（第30个月除外；p<0.05），6个月后平均缺损明显更小（p<0.05）。
